

1 **Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine**

2 Nasamon Wanlapakorn¹, Ritthideach Yorsaeng¹, Harit Phowatthanasathian¹, Nungruthai

3 Suntronwong¹, Sitthichai Kanokudom¹, Natthinee Sudhinaraset¹, Yong Poovorawan^{1,2*}

4 ¹Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine,
5 Chulalongkorn University, Bangkok, Thailand.

6 ²FRS(T), the Royal Society of Thailand, Sanam Sueapa, Dusit, Bangkok 10330, Thailand.

7

8 Address for correspondence: Yong Poovorawan, M.D. Center of Excellence in Clinical

9 Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University,

10 Bangkok, Thailand. E-mail: yong.p@chula.ac.th

11

12

13

14

15

16

17

18

19

20

21

22

23

24 **Abstract**

25 **Introduction:** In August 2021, Thailand imported the BNT162b2 mRNA COVID-19
26 vaccine. The prioritised group to receive the BNT162b2 vaccine were health professionals.
27 The BNT162b2 vaccine scheduled for healthcare workers were two-dose regimen
28 administered three weeks apart, the third dose booster in two-dose inactivated CoronaVac
29 vaccine recipients or as a second dose in health professionals who had received the
30 CoronaVac or adenoviral-vectored (ChAdOx1-S) vaccine as the first dose regardless of the
31 interval between the first and second dose.

32 **Methods:** This study aims to evaluate the immunogenicity of the heterologous prime boost
33 CoronaVac followed by BNT162b2 in health professionals.

34 **Results:** The CoronaVac/BNT162b2 vaccine recipients elicited higher neutralizing activity
35 against the original Wuhan and all variants of concern than in the recipients of the two-dose
36 CoronaVac.

37 **Conclusions:** The heterologous CoronaVac/BNT162b2 could be used as an alternative
38 regimen in countries experiencing the vaccine shortages and in individuals experiencing the
39 adverse events following CoronaVac.

40

41 **Key words:** heterologous, inactivated, mRNA, COVID-19, vaccine

42

43

44 **Introduction**

45 In August 2021, Thailand imported the BNT162b2 mRNA COVID-19 vaccine. The
46 prioritised group to receive the BNT162b2 vaccine were health professionals. The BNT162b2
47 vaccine scheduled for healthcare workers were two-dose regimen administered three weeks
48 apart, the third dose booster in two-dose inactivated CoronaVac vaccine recipients or as a
49 second dose in health professionals who had received the CoronaVac or adenoviral-vectored
50 (ChAdOx1-S) vaccine as the first dose regardless of the interval between the first and second
51 dose.

52 It is possible to mix and match vaccines in specific situations such as a vaccine
53 shortage or adverse reactions following vaccine administration. The interval between the first
54 and the second dose may vary according to the availability of a vaccine. This study aims to
55 assess and provide preliminary data on the immunogenicity of heterologous prime/boost
56 inactivated vaccine followed by the BNT162b2 mRNA vaccine at different intervals amongst
57 Thai health professionals.

58 **Methods**

59 We performed a cross-sectional study in which leftover sera samples from
60 participants seeking antibody testing following vaccination at the Center of Excellence in
61 Clinical Virology, Faculty of Medicine, Chulalongkorn University between September and
62 October 2021 were further analysed. Only samples from participants who received
63 heterologous prime/boost inactivated CoronaVac followed by BNT162b2 vaccine (hereafter
64 referred to as CV/BNT162b2) were used. The study protocol was approved by the Research
65 Ethics Committee of the Faculty of Medicine, Chulalongkorn University (IRB 870/64).

66 Two reference groups of Thai individuals vaccinated with two-dose CoronaVac
67 (hereafter referred to as CV/CV) (n=170) and BNT162b2 regimen (hereafter referred to as
68 BNT162b2/BNT162b2) (n=19) were included in the analysis.

69 Venous blood samples were collected between 21-35 days after the second dose
70 vaccination and tested for SARS-CoV-2 spike receptor-binding domain (RBD) IgG by
71 SARS-CoV-2 IgG II Quant assay (Abbott Diagnostics, Abbott Park, IL), SARS-CoV-2 spike
72 RBD total immunoglobulin (Ig) by Elecsys SARS-CoV-2 S (Roche Diagnostics, Basel,
73 Switzerland), and anti-spike protein 1 (S1) IgA by an enzyme-linked immunosorbent assay
74 (ELISA) (Euroimmun, Lübeck, Germany).

75 The neutralizing activity was tested against the original Wuhan strain and variants of
76 concern, B.1.1.7, B.1.617.2, and B.1.351, by an ELISA-based surrogate virus neutralization
77 test (sVNT); cPassTM SARS-CoV-2 neutralizing antibody detection kit (GenScript Biotech,
78 Piscataway, NJ). The methods were described in a previous study [1].

79 The differences in antibody responses between groups were calculated using the
80 Mann-Whitney U test. A *p*-value <0.05 was considered statistically significant.

81

82

83 **Results**

84 There were significantly more women in the CV/BNT162b2 group (Table 1) due to
85 the fact that healthcare professionals enrolled in this study were mostly female nurses.
86 Furthermore, the CV/BNT162b2 group was younger than the CV/CV group (χ^2 test p -value
87 <0.001). Unlike the homologous CV/CV and BNT162b2/BNT162b2 vaccination cohorts,
88 there were variations in intervals between the first and second dose vaccinations among the
89 heterologous CV/BNT162b2 vaccinees. We analysed the immunogenicity data of the
90 heterologous CoronaVac/BNT162b2 vaccinees in two sets. The first set were those who
91 received two vaccines 21-28 days apart, now termed the short-interval CV/BNT162b2
92 regimen, and the second set were those who received two vaccines for more than 7 weeks
93 apart, now termed long-interval CV/BNT162b2 regimen (Table 2).

94 Analysis of RBD-specific total Ig following a two-dose vaccination showed that
95 regimens including BNT162b2 elicited higher responses compared to the homologous
96 CoronaVac regimen (Figure 1A). Within the CV/BNT162b2 regimen, the long-interval
97 regimen elicited higher RBD total Ig following the second dose vaccination compared to the
98 short-interval regimen.

99 When only considering anti-RBD IgG, all BNT162b2-incorporated regimens also
100 showed higher anti-RBD IgG levels compared to the homologous CoronaVac regimen
101 (Figure 1B). The long-interval CV/BNT162b2 regimen elicited higher anti-RBD IgG than the
102 short-interval CV/BNT162b2 and homologous BNT162b2 regimens.

103 In addition, anti-S1 IgA was detected in only BNT162b2-incorporated vaccination
104 schedules at similar levels, while no significant amount of anti-S1 IgA was detected in
105 homologous inactivated CV/CV regimen (Figure 1C).

106 Comparison of neutralizing activities (presented as percent inhibition) showed that the
107 long-interval CV/BNT162b2 regimen elicited higher neutralizing activities against the wild-

108 type and all variants of concerns than the short-interval CV/BNT162b2 regimen (Figure 2A-
109 D). The long-interval CV/BNT162b2 regimen also elicited higher neutralizing activities
110 against the alpha and beta SARS-CoV-2 variants compared to the BNT162b2/BNT162b2
111 regimens (Figure 2B-C).

112 **Discussion**

113 Our study found that both the short and long-interval heterologous regimens with
114 CoronaVac followed by BNT162b2 induced higher SARS-CoV-2 RBD-specific antibody
115 responses and neutralizing activities against wild type and variants of concern than that of the
116 licensed two-dose CoronaVac vaccine with proven 65–83% efficacy against symptomatic
117 COVID-19 [2, 3]. In addition, the SARS-CoV-2 RBD-specific total Ig and IgG responses
118 elicited by CoronaVac/BNT162b2 were comparable to those elicited by homologous two-
119 dose BNT162b2 vaccine. Although the antibody levels alone do not directly correlate with
120 certain levels of protection, a previous study showed that higher anti-spike IgG, anti-RBD
121 IgG, and neutralizing antibody titres are all associated with a lower risk of symptomatic
122 COVID-19 [4].

123 Comparison between the short and long-interval CoronaVac/BNT162b2 schedules
124 found the long-interval regimen to have elicited higher anti-RBD immunoglobulin and IgG
125 and higher neutralizing activities against alpha and beta SARS-CoV-2 variants than the short-
126 interval regimen. These results align with other COVID-19 vaccine studies which showed
127 increased antibody responses with an extended prime-boost interval [5, 6]. However, the
128 long-interval heterologous regimen as a COVID-19 vaccination option has not been publicly
129 recommended due to the fact that one dose immunisation by certain vaccines may not be
130 effective in preventing the disease [7], thus leaving the one-dose vaccinated individuals at
131 risk. Amidst the COVID-19 pandemic, the goal of vaccination was to ramp up the protective
132 immunity among the population with a two-dose regimen in a short amount of time.

133 Aside from heightened immunoglobulin titers and inhibition percentages of
134 neutralizing activities in BNT162b2-incorporated regimens compared to the
135 CoronaVac/CoronaVac regimen, a notable discrepancy of anti-S1 IgA was observed. Serum
136 anti-spike-1 protein-specific IgA OD/CO ratios were detected only in the BNT162b2-
137 incorporated regimen. Limited data is available on the clinical benefit of serum IgA in
138 protection; however, a recent in vitro experimental study has shown that serum IgA
139 contributed to the neutralization of the SARS-CoV-2 [8-10].

140 Our study had a few noteworthy limitations. Firstly, the demographic discrepancies of
141 the short and long-interval heterologous regimen cohorts heavily favour young females.
142 Cohort sizes were relatively small, therefore requiring further studying with a larger sample
143 size. Secondly, this study did not investigate the reactogenicity of the heterologous schedule.
144 Lastly, efficacy data from more extensive trials are needed to comprehensively determine the
145 benefits of heterologous CoronaVac followed by BNT162b2 regimen across all age groups in
146 different countries facing different emerging SARS-CoV-2 variants.

147 **Conclusions**

148 In low- and middle-income countries experiencing a vaccine shortage and emerging
149 variants, heterologous COVID-19 vaccine schedules have the potential to accelerate vaccine
150 rollout. Additionally, adverse events following vaccination called into question whether a
151 different combination would be advantageous in reducing the chance of adverse reactions
152 following the second dose of some vaccines, for example, mRNA vaccine which is related to
153 myocarditis more frequently after the second than first dose vaccination [11]. Results of this
154 preliminary investigation call for a larger safety and efficacy trial especially in males between
155 16-29 years of age, due to possible cases of myocarditis following the second dose of mRNA
156 vaccine [12]. Further experimentation into T-cells responses is also of interest to fully
157 elucidate immunological response to the heterologous regimen.

158 **Acknowledgements**

159 This work was supported by The National Research Council of Thailand (NRCT), Health
160 Systems Research Institute, The Center of Excellence in Clinical Virology of Chulalongkorn
161 University, and King Chulalongkorn Memorial Hospital. Nungruthai Suntronwong was
162 supported by the second Century Fund (C2F) fellowship of Chulalongkorn University. We
163 would like to thank Dr. Pussadee Hirasas, MD from the Navy Health Center.
164 Somdechphrapinklao Hospital for the contribution to this project.

165 **Conflict of Interest**

166 The authors declare no conflict of interest.

167

168 **Reference**

- 169 [1] Wanlapakorn N, Suntronwong N, Phowatthanasathian H, et al. Safety and
170 immunogenicity of heterologous and homologous inactivated and adenoviral-vectored
171 COVID-19 vaccines in healthy adults. medRxiv 2021.11.04.21265908 [Preprint]. 2021 [cited
172 2021 Nov 6] Available from:
173 <https://www.medrxiv.org/content/10.1101/2021.11.04.21265908v2>
174 <https://doi.org/10.1101/2021.11.04.21265908>
- 175 [2] Fadlyana E, Rusmil K, Tarigan R, et al. A phase III, observer-blind, randomized, placebo-
176 controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated
177 vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia. Vaccine. 2021
178 Oct 22;39(44):6520-6528. doi: 10.1016/j.vaccine.2021.09.052. Epub 2021 Sep 24. PMID:
179 34620531; PMCID: PMC8461222.
- 180 [3] Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-
181 virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised,
182 placebo-controlled, phase 3 trial in Turkey. Lancet. 2021 Jul 17;398(10296):213-222. doi:

- 183 10.1016/S0140-6736(21)01429-X. Epub 2021 Jul 8. PMID: 34246358; PMCID:
184 PMC8266301.
- 185 **[4]** Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and
186 asymptomatic SARS-CoV-2 infection. *Nat Med*. 2021 Sep 29. doi: 10.1038/s41591-021-
187 01540-1. Epub ahead of print. PMID: 34588689.
- 188 **[5]** Rogawski McQuade ET, Breskin A. Longer intervals and extra doses of ChAdOx1
189 nCoV-19 vaccine. *Lancet*. 2021 Sep 11;398(10304):933-935. doi: 10.1016/S0140-
190 6736(21)01817-1. Epub 2021 Sep 1. PMID: 34480860; PMCID: PMC8409898.
- 191 **[6]** Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated
192 SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind,
193 placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis*. 2021 Feb;21(2):181-192. doi:
194 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17. PMID: 33217362; PMCID:
195 PMC7832443.
- 196 **[7]**. Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated SARS-CoV-2
197 Vaccine in Chile. *N Engl J Med*. 2021 Sep 2;385(10):875-884. doi:
198 10.1056/NEJMoa2107715. Epub 2021 Jul 7. PMID: 34233097; PMCID: PMC8279092.
- 199 **[8]** Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody
200 response to SARS-CoV-2. *Sci Transl Med*. 2021 Jan 20;13(577):eabd2223. doi:
201 10.1126/scitranslmed.abd2223. Epub 2020 Dec 7. PMID: 33288662; PMCID: PMC7857408.
- 202 **[9]** Klingler J, Weiss S, Itri V, et al. Role of Immunoglobulin M and A Antibodies in the
203 Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2. *J Infect Dis*. 2021 Mar
204 29;223(6):957-970. doi: 10.1093/infdis/jiaa784. PMID: 33367897; PMCID: PMC7798948.
- 205 **[10]** Wang Z, Lorenzi JCC, Muecksch F, et al. Enhanced SARS-CoV-2 neutralization by
206 dimeric IgA. *Sci Transl Med*. 2021 Jan 20;13(577):eabf1555. doi:
207 10.1126/scitranslmed.abf1555. Epub 2020 Dec 7. PMID: 33288661; PMCID: PMC7857415.

208 [11] Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 Vaccine After
209 Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on
210 Immunization Practices - United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021
211 Jul 9;70(27):977-982. doi: 10.15585/mmwr.mm7027e2. PMID: 34237049; PMCID:
212 PMC8312754.

213 [12] Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large
214 Health Care Organization. N Engl J Med. 2021 Oct 6:NEJMoa2110737. doi:
215 10.1056/NEJMoa2110737. Epub ahead of print. PMID: 34614329; PMCID: PMC8531986.

216
217
218
219
220
221
222
223
224
225
226
227

228 **Table 1.** Characteristics of the participants in all vaccinated groups.

Characteristics	CV/CV (n = 170)	Short-interval CV/BNT162b2 (n = 66)	Long-interval CV/BNT162b2 (n = 10)	BNT162b2/BNT162b2 (n = 19)
Sex, Female no. (%)	89 (52.4%)	63 (93.9%)	8 (80.0%)	12 (63.2%)
Age years, mean [SD] (min-max)	42.3 [9.6] (18.0-59.0)	24.1 [6.2] (20.0-49.0)	31.1 [11.2] (20.0-57.0)	34.4 [11.9] (14.0-54.0)
Interval between the 1 st and 2 nd dose (days)	23.0 [21.0, 26.0]	21.0 [21.0, 21.0]	107.5 [77.75, 137.5]	21.0 [21.0, 24.0]
Median [IQR] (min-max)	(21.0-28.0)	(21.0-26.0)	(50.0-156.0)	(21.0-31.0)
Interval between the last dose and blood collection (days)	29.0 [28.0, 31.0]	29.0 [29.0-35.0]	30.50 [29.0, 35.0]	34.0 [31.0, 35.0]
Median [IQR] (min-max)	(27.0-49.0)	(21.0-35.0)	(29.0-35.0)	(31.0-35.0)

229

230

231

232

233

234

235

236

237

238

239

240

241


242

243

244 **Table 2.** The geometric mean titer (GMT) of anti-receptor-binding domain (RBD) Ig and IgG, anti-spike protein 1 IgA and percentage inhibition
 245 against wild type and variants of SARS-CoV-2 in serum from individuals who received homologous CoronaVac (CV/CV), heterologous
 246 CoronaVac followed by BNT162b2 (CV/BNT162b2), and homologous BNT162b2 (BNT162b2/BNT162b2) vaccines.
 247

Results	CV/CV (n = 170)	Short-interval CV/BNT162b2 (n = 66)			Long-interval CV/BNT162b2 (n = 10)	BNT162b2/BNT162b2 (n = 19)
		Total (all age)	18-29 years old (n = 52)	30-50 years old (n = 14)		
Anti-RBD Ig, U/mL	97.9	1042	1051	1010	10485	1963
GMT [95% CI] (range)	[82.6, 116.1] (0.40-1028)	[828.6, 1311] (116.4-12865)	[815.8, 1355] (116.4-8891)	[550.9, 1852] (224.5-12865)	[7228, 15209] (4894-19966)	[1378, 2798] (314.2-4310)
Anti-RBD IgG, BAU/mL	128.0	1475	1613	1058	2683	1651
GMT [95% CI] (range)	[113.7, 144.1] (14.7-961.4)	[1267, 1716] (181.5-4303)	[1372, 1895] (181.5-4303)	[723.5, 1547] (225.7-3911)	[2075, 3469] (1332-4827)	[1182, 2306] (279.4-5169)
anti-S1 IgA, OD/CO ratio	0.88	6.55	7.25	4.49	9.00	5.62
Median [IQR] (range)	[0.55, 1.79] (0.15-9.00)	[4.87, 9.00] (1.14-9.00)	[5.43, 9.00] (1.14-9.00)	[3.05, 7.85] (1.25-9.00)	[7.79, 9.00] (3.44-9.00)	[4.51, 8.37] (2.01-8.37)
sVNT (Wild-type), % Inhibition	66.60 [48.86, 79.41]	95.45 [93.00, 96.63]	95.45 [93.60, 96.68]	95.30 [92.65, 96.78]	97.35 [96.55, 97.55]	97.40 [96.30, 97.70]

Median [IQR] (range)	(21.13-92.50)	(64.20-98.20)	(64.20-97.60)	(89.90-98.20)	(96.20-98.20)	(83.50-98.10)
sVNT (B.1.1.7), % Inhibition	42.11	84.70	85.40	80.30	97.85	93.70
Median [IQR] (range)	[28.97, 58.31] (7.21-73.15)	[78.53, 88.60] (45.60-97.80)	[78.90, 88.60] (45.60-97.50)	[75.75, 86.70] (65.40-97.80)	[97.20, 98.00] (96.50-98.00)	[88.30, 95.10] (54.90-96.30)
sVNT (B.1.351), % Inhibition	34.86	77.25	76.80	77.25	95.40	88.60
Median [IQR] (range)	[20.46, 47.33] (4.15-72.43)	[69.28, 82.53] (45.30-96.70)	[69.63, 82.58] (45.30-95.80)	[64.98, 82.23] (57.50-96.70)	[93.98, 96.25] (89.30-97.00)	[80.30, 91.20] (52.20-93.60)
sVNT (B.1.617.2), % Inhibition	48.93	92.95	93.15	89.00	97.35	97.10
Median [IQR] (range)	[36.12, 63.42] (12.46-85.45)	[89.08, 94.95] (67.70-98.00)	[90.90, 95.10] (67.70-98.00)	[84.50, 91.83] (83.40-97.30)	[96.55, 97.93] (86.50-98.00)	[95.00, 97.60] (68.70-98.10)



250 **Figure 1. Binding antibody specific for SARS-CoV-2.** A) Total immunoglobulin specific to
251 the RBD (anti-RBD Ig) and B) Anti-RBD IgG and C) Anti-spike protein 1 IgA (anti-S1 IgA)
252 at 21-35 days after completion of two-dose vaccination. Data points are the reciprocals of the
253 individual. Lines indicate geometric means and bars indicate 95% confidence intervals for
254 anti-RBD Ig and anti-RBD IgG, and median and interquartile ranges for anti-S1 IgA. Dotted
255 lines denote the positive cut-off levels according to the manufacturer's instructions. ***
256 indicates $p \leq 0.001$, ** indicates $p \leq 0.01$. * indicates $p \leq 0.05$, ns denotes no statistical
257 significance.

258

259

260

261

262

263

264

265

266

267

268

269


270

271

272

273

274



275

276 **Figure 2. Serum neutralizing activities against wild-type SARS-CoV2 (D) and variants**

277 **of concern (alpha (E), beta (F), and delta (G)) in vaccinated individuals at 21-35 days**

278 **after completion of two-dose vaccination.** The data points are the reciprocals of the

279 individual. Lines indicate median and I-bars indicate interquartile ranges. Dotted lines denote

280 the positive cut-off levels according to the manufacturer's instructions. sVNT denotes

281 surrogate virus neutralization test (sVNT). *** indicates $p \leq 0.001$, ns denotes no statistical

282 significance.